REC Stock Overview
Engages in the research, development, production, and sale of pharmaceuticals in Italy and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 4/6 |
| Past Performance | 6/6 |
| Financial Health | 4/6 |
| Dividends | 5/6 |
My Notes
Capture your thoughts, links and company narrative
Community Narratives
Create a narrativeNarratives bring a range of perspectives from our community.
Recordati Industria Chimica e Farmaceutica S.p.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €54.90 |
| 52 Week High | €55.10 |
| 52 Week Low | €47.28 |
| Beta | 0.41 |
| 1 Month Change | 8.93% |
| 3 Month Change | 2.14% |
| 1 Year Change | 10.33% |
| 3 Year Change | 6.60% |
| 5 Year Change | 36.26% |
| Change since IPO | 4,125.68% |
Recent News & Updates
Estimating The Fair Value Of Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC)
Jan 05
Do Recordati Industria Chimica e Farmaceutica's (BIT:REC) Earnings Warrant Your Attention?
Dec 18We Like The Quality Of Recordati Industria Chimica e Farmaceutica's (BIT:REC) Earnings
Nov 18Recordati Industria Chimica e Farmaceutica (BIT:REC) Is Due To Pay A Dividend Of €0.60
Nov 14Recent updates
Estimating The Fair Value Of Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC)
Jan 05Do Recordati Industria Chimica e Farmaceutica's (BIT:REC) Earnings Warrant Your Attention?
Dec 18We Like The Quality Of Recordati Industria Chimica e Farmaceutica's (BIT:REC) Earnings
Nov 18Recordati Industria Chimica e Farmaceutica (BIT:REC) Is Due To Pay A Dividend Of €0.60
Nov 14Earnings Beat: Recordati Industria Chimica e Farmaceutica S.p.A. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Nov 13Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC) Not Flying Under The Radar
Oct 31Estimating The Fair Value Of Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC)
Sep 07We Think Recordati Industria Chimica e Farmaceutica (BIT:REC) Can Stay On Top Of Its Debt
Aug 20Earnings Miss: Recordati Industria Chimica e Farmaceutica S.p.A. Missed EPS By 31% And Analysts Are Revising Their Forecasts
Aug 02Recordati Industria Chimica e Farmaceutica S.p.A.'s (BIT:REC) Business Is Yet to Catch Up With Its Share Price
Aug 01Estimating The Intrinsic Value Of Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC)
May 26Recordati Industria Chimica e Farmaceutica (BIT:REC) Will Pay A Larger Dividend Than Last Year At €0.63
May 10Recordati Industria Chimica e Farmaceutica's (BIT:REC) Dividend Will Be Increased To €0.63
Apr 25Recordati Industria Chimica e Farmaceutica S.p.A.'s (BIT:REC) Share Price Could Signal Some Risk
Apr 23If EPS Growth Is Important To You, Recordati Industria Chimica e Farmaceutica (BIT:REC) Presents An Opportunity
Apr 08Recordati Industria Chimica e Farmaceutica (BIT:REC) Is Increasing Its Dividend To €0.63
Mar 23Is Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC) Expensive For A Reason? A Look At Its Intrinsic Value
Jan 27Shareholder Returns
| REC | IT Pharmaceuticals | IT Market | |
|---|---|---|---|
| 7D | 2.9% | -2.5% | 3.2% |
| 1Y | 10.3% | -4.2% | 16.6% |
Return vs Industry: REC exceeded the Italian Pharmaceuticals industry which returned -4.2% over the past year.
Return vs Market: REC underperformed the Italian Market which returned 16.6% over the past year.
Price Volatility
| REC volatility | |
|---|---|
| REC Average Weekly Movement | 2.6% |
| Pharmaceuticals Industry Average Movement | 5.5% |
| Market Average Movement | 4.3% |
| 10% most volatile stocks in IT Market | 7.6% |
| 10% least volatile stocks in IT Market | 2.5% |
Stable Share Price: REC has not had significant price volatility in the past 3 months compared to the Italian market.
Volatility Over Time: REC's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1926 | 4,455 | Rob Koremans | www.recordati.com |
Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceuticals in Italy and internationally. It operates through Specialty and Primary Care and Rare Diseases segments. The company’s product pipeline includes REC 0559 which is in Phase II for the treatment of Neurotrophic Keratitis; REC 0545 for acute decompensation in maple syrup urine diseases; ISTURISA for endogenous Cushing’s syndrome; and CYSTADROPS for the treatment of cystine crystal deposits in the cornea.
Recordati Industria Chimica e Farmaceutica S.p.A. Fundamentals Summary
| REC fundamental statistics | |
|---|---|
| Market cap | €11.23b |
| Earnings (TTM) | €423.12m |
| Revenue (TTM) | €2.27b |
26.5x
P/E Ratio4.9x
P/S RatioIs REC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| REC income statement (TTM) | |
|---|---|
| Revenue | €2.27b |
| Cost of Revenue | €666.44m |
| Gross Profit | €1.60b |
| Other Expenses | €1.18b |
| Earnings | €423.12m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.07 |
| Gross Margin | 70.63% |
| Net Profit Margin | 18.65% |
| Debt/Equity Ratio | 81.6% |
How did REC perform over the long term?
See historical performance and comparisonDividends
2.2%
Current Dividend Yield60%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/19 16:10 |
| End of Day Share Price | 2025/01/17 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Recordati Industria Chimica e Farmaceutica S.p.A. is covered by 23 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Paola Saglietti | Banca Akros S.p.A. (ESN) |
| Charles Pitman-King | Barclays |
| Vincent Meunier | BNP Paribas Exane |